Paper
0
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Authors
Alberto Bongiovanni,Chiara Liverani
Flavia Foca,Francesca Bergamo,Silvana Leo,Sara Pusceddu,Fabio Gelsomino,Maria Brizzi,Giovanni Meglio,Francesca Spada,Stefano Tamberi,Ivan Lolli,Mauro Cives,Riccardo Marconcini,Francesca Pucci,Rossana Berardi,Lorenzo Antonuzzo,Giuseppe Badalamenti,Massimo Maïo,Federica Recine,Silvia Vanni,Michela Tebaldi,Toni Ibrahim,Britt Rudnas,Oriana Nanni,Nicoletta Ranallo,Laura Crudi
+25 authors
,Luana CalabròJournal
Published
May 25, 2024
Show more
Save
Tip0
TipSave
Abstract
Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these regimens in metastatic NEC patients.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.